Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy-Reference-Cited by-同舟云学术

Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy

Published:2018-12 Issue: Volume: Page:
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

da Costa Jose Batista,Gibb Ewan A.,Nykopp Timo K.,Mannas Miles,Wyatt Alexander W.^ORCID,Black Peter C.^ORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference63 articles.

1. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma;Siefker-Radtke;J Urol,2018

2. Erdafitinib, a panfibroblast growth factor receptor inhibitor, in patients with metastatic or unresectable urothelial carcinoma and fgfr alterations;Loriot,2018

3. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial;Petrylak;Lancet,2017

4. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2006

5. Genome sequencing identifies a basis for everolimus sensitivity;Iyer;Science,2012

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer;BMC Cancer;2024-08-06

2. Relationship between clonal evolution and drug resistance in bladder cancer: A genomic research review;Pharmacological Research;2024-08

3. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer;European Journal of Medical Research;2024-02-09

4. MVMSGAT: Integrating Multiview, Multi-Scale Graph Convolutional Networks with Biological Prior Knowledge for Predicting Bladder Cancer Response to Neoadjuvant Therapy;Applied Sciences;2024-01-12

5. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer;2024-01-03